Braintree Manufacturing Innovation Centre receives MHRA licence to manufacture advanced therapies
The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, today announces that its Braintree Manufacturing Innovation Centre (Braintree MIC) has successfully received a Medicines and Healthcare products Regulatory Agency (MHRA) Manufacturers and Importers Authorisation for Investigational Medicinal Products (MIA(IMP)) and associated Good Manufacturing Practice (GMP) certificate.
Published on the 5th of March 2024. Read the full news here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (5 novembre 2024). Braintree Manufacturing Innovation Centre receives MHRA licence to manufacture advanced therapies. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/12mia





